Effects of Teriparatide Treatment and Discontinuation in Postmenopausal Women and Eugonadal Men with Osteoporosis

Benjamin Z. Leder(Massachusetts General Hospital), Joel S. Finkelstein(University of Massachusetts Chan Medical School), Hang W. Lee(Massachusetts General Hospital), Jason J. Wyland(Harvard University), Sherri‐Ann M. Burnett‐Bowie(Massachusetts General Hospital), Robert M. Neer(Brigham and Women's Hospital)
The Journal of Clinical Endocrinology & Metabolism
May 13, 2009
10.1210/jc.2008-2630
Cited by 137

Related Papers

Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men
|New England Journal of Medicine|2013|777
Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial.
|BMJ|1980|585
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial
|The Lancet|2015|574
Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial
|The Lancet|2013|491
Regulation of C-Terminal and Intact FGF-23 by Dietary Phosphate in Men and Women
|Journal of Bone and Mineral Research|2006|455